References

AABB. Misconceptions about TRALI risk reduction recommendations: Female plasma usage. Accessed at www.aabb.org/Content/News_and_Media/Latest_News/lntrali012907.htm on June 18, 2009. Content no longer available.

American Red Cross. Blood Types. Accessed at www.redcrossblood.org/learn-about-blood/blood-types on July 19, 2011.

American Red Cross. Donating Blood: Eligibility Guidelines. Accessed at www.redcrossblood.org/donating-blood/eligibility-requirements on July 20, 2011.

American Red Cross. A Compendium of transfusion Practice Guidelines. First Edition 2010. Accessed at www.redcrossblood.org/sites/arc/files/pdf/Practice-Guidelines-Nov2010-Final.pdf on July 20, 2011.

American Red Cross. Blood Testing. Accessed at www.redcrossblood.org/learn-about-blood/what-happens-donated-blood/blood-testing on July 20, 2011.

Babic A, Kaufman RM. Principles of platelet transfusion therapy. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, et al, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2009:2219−2223.

Centers for Disease Control and Prevention. Fatal bacterial infections associated with platelet transfusions – United States, 2004. MMWR. 2005;54:168−170.

Centers for Disease Control and Prevention. Parasites - American Trypanosomiasis (also known as Chagas Disease): Blood Screening FAQs. Accessed at http://www.cdc.gov/parasites/chagas/gen_info/screening.html on July 22, 2011.

Cushing MM, Ness PM. Principles of red blood cell transfusion. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, et al, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2009:2209−2218.

Dodd RY, Notari EP 4th, Stramer SL for the Transmissible Diseases Department, American Red Cross. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42(8):975−979.

Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol. 2007;14:671−676.

Domen RE. Blood Product Transfusions in the Hematologic Malignancies. In Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York: McGraw-Hill; 2007:1127−1138.

Eder A. Blood Donors with a history of cancer. In: Eder A, Bianco C, eds. Screening Blood Donors: Science, Reason, and the Blood Donation Questionnaire. Bethesda, Md: AABB Press: 2007:77−92.

Edgren G, Hjalgrim H, Reilly M, et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet. 2007;369:1724−1730.

Food and Drug Administration, Blood Products Advisory Committee meeting transcripts, 1999-2011. Accessed at www.fda.gov/ohrms/dockets/ac/acmenu.htm on July 21, 2011.

Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: An Acceptable Circular of Information for the Use of Human Blood and Blood Components. Updated December 2009. Accessed at: www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM187348.pdf on July 21, 2011.

Food and Drug Administration, FDA News Release. FDA Clears for Marketing First Rapid Test to Screen for Bacterial Contamination in Blood Platelets. Accessed at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108986.htm on July 20, 2011.

Glaspy J. Disorders of blood cell production in clinical oncology. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Churchill Livingstone; 2008:677−692.

Hay SN, Scanga L, Brecher ME. Life, death, and the risk of transfusion: a university hospital experience. Transfusion. 2006;46(9):1491−1493.

Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108(3):759−769.

Henkel-Honke T, Oleck M. Artificial oxygen carriers: a current review. AANA J. 2007;75:205−211.

Higgins MJ, Blackall DP. Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion. Curr Hematol Rep. 2005;4:470−476.

Hjalgrim H, Edgren G, Rostgaard K, et al. Cancer Incidence in Blood Transfusion Recipients. J Natl Cancer Inst. 2007;99:1864-1874.

Marik PE. The hazards of blood transfusion. British Journal of Hospital Medicine. 2009;70(1):12−15.

Marik PE, Corwin HL. Acute lung injury following blood transfusion: expanding the definition. Crit Care Med. 2008;36(11):3080−3084.

Morris-Stiff G, Steel A, Savage P, et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant. 2004;4:444−446.

Silliman CC. Transfusion-related acute lung injury (TRALI), in Hematology 2004, American Society of Hematology; 2004: 461-466. Accessed at www.asheducationbook.org on June 19, 2009. Content no longer available.

Triulzi DJ. Transfusion-related acute lung injury: an update. Hematology Am Soc Hematol Educ Program. 2006:497−501.

Vandegriff KD, Winslow RM. Hemospan: design principles for a new class of oxygen therapeutic. Artif Organs. 2009;33(2):133−138.

Yang H, Lee J, Seed CR, Keller AJ. Can blood tranfusion transmit cancer? A literature review. Transfus Med Rev. 2010;24(3):235−243.

Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion. 2009 Apr 28.